Merrill Lynch Stick to Their Buy Rating for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, which is more or less 9.11 % above the existing share price of $76.07.

Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the earliest quarter of 2021.

The present opinion among eleven TipRanks analysts is actually for a reasonable Buy rating of shares in CVS Health, with an average price target of $84.

The analysts price targets range from a high of $101 to a low of sixty one dolars.

In the newest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is actually $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is now ranked with four stars on a 0 5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment extends pharmacy benefit management strategies. The Long or retail Term Care segment has selling of prescription medications and assortment of general merchandise.

The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products as well as related services, including medical, pharmacy, dental, behavioural health, medical control capabilities. The Corporate segment involves in offering management as well as administrative services. The company was developed by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.